Fred Hutch's Value in Cancer Care conference, held November 6, focused on patient and provider burnout; the growing data ...

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...

A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...

On Oct. 9, 2025, Fred Hutch Cancer Center employees with decades of service were honored at a luncheon celebrating their ...

Our research on cell-based therapies also includes cutting-edge immunotherapies that harness the patient’s own immune cells to fight disease, including genetic engineering of immune cells to attack ...

Affiliate Professor, Herbold Computational Biology Program, Public Health Sciences Division, Fred Hutch Affiliate Professor, Herbold Computational Biology Program Public Health Sciences Division, Fred ...

Today, Fred Hutch announced that in 2025 the Obliteride community raised $9.2 million for groundbreaking research. This amount brings Obliteride’s cumulative fundraising total to more than $67 million ...

New Fred Hutch Cancer Center viral immunologist Dr. Paul Thomas is working to turn the "incredible potential" of the immune system into real-life diagnostic and therapeutic applications. He studies ...

In this conversation, Petros Grivas, MD, PhD, discusses his new podcast aimed at exploring the latest developments in cancer care and research. He emphasizes the importance of learning from colleagues ...

Philanthropy fuels Fred Hutch’s breakthroughs. Our community's support drives life-changing discoveries, strengthens patient and caregiver experiences, and helps build the next generation of ...